Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - iné antineoplastické látky - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alkaloid - int d.o.o., slovinsko - ibuprofén - 07 - analgetica, antipyretica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

inn-farm d.o.o., slovinsko - ibuprofén - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

viatris limited, Írsko - ibuprofén - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mylan ireland limited, Írsko - ibuprofén - 29 - antirheumatica, antiphlogistica, antiuratica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

nutra essential, otc, s.l., Španielsko - ibuprofén - 07 - analgetica, antipyretica

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer europe ma eeig  - rimegepant - poruchy migrény - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Európska únia - slovenčina - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - hiv infekcie - antivirotiká na systémové použitie - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Európska únia - slovenčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - dexmedetomidine - premedication - psycholeptika - pre sedácia dospelých jednotke intenzívnej starostlivosti (jednotke intenzívnej starostlivosti) pacientov vyžadujúcich sedácia úroveň nie je hlbšie ako vzrušenie ako reakciu na verbálnej stimulácie (zodpovedajúce richmond nepokoj-sedácia rozsahu (rass) 0 -3). pre sedácia non-intubated dospelých pacientov pred a/alebo počas diagnostické alebo chirurgické postupy vyžadujúce sedácia, som. procesné/hore sedácia.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glenmark pharmaceuticals s.r.o., Česká republika - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)